Correspondence 0001213900-23-053639 from Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc.
Date: June 30, 2023 · CIK: 0001860657 · Accession: 0001213900-23-053639
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272469
Letter
Re:
June 30, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Allarity Therapeutics, Inc.
Registration Statement on Form S-1
(File No. 333-272469)
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), A.G.P./ALLIANCE GLOBAL PARTNERS, as Placement Agent, hereby joins Allarity Therapeutics, Inc. (the “Company”) in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-272469) (the “Registration Statement”) to become effective on Wednesday, July 5, 2023, at 5:30 p.m., Eastern Time, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel Lewis Brisbois Bisgaard & Smith LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 of the General Rules and Regulations under the Act, the undersigned advises that copies of the Preliminary Prospectus, dated June 30, 2023, are expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The Placement Agent is aware of their obligations under and confirm that they are complying with the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, including the delivery requirement contained in such Rule.
Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS
Show Raw Text
CORRESP
1
filename1.htm
June 30, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Allarity Therapeutics, Inc.
Registration Statement on Form S-1
(File No. 333-272469)
Ladies and Gentlemen:
In accordance with Rule 461
of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), A.G.P./ALLIANCE
GLOBAL PARTNERS, as Placement Agent, hereby joins Allarity Therapeutics, Inc. (the “Company”) in requesting that the Securities
and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-272469) (the “Registration
Statement”) to become effective on Wednesday, July 5, 2023, at 5:30 p.m., Eastern Time, or as soon thereafter as practicable, or
at such other time as the Company or its outside counsel Lewis Brisbois Bisgaard & Smith LLP, request by telephone that such Registration
Statement be declared effective.
Pursuant to Rule 460 of the
General Rules and Regulations under the Act, the undersigned advises that copies of the Preliminary Prospectus, dated June 30, 2023, are
expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears to be reasonable to
secure adequate distribution of the Preliminary Prospectus.
The Placement Agent is aware
of their obligations under and confirm that they are complying with the provisions of Rule 15c2-8 under the Securities Exchange Act of
1934, as amended, including the delivery requirement contained in such Rule.
Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS
By:
/s/ Thomas J. Higgins
Name:
Thomas J. Higgins
Title:
Managing Director